Vectibix

Type: Product

Name: Vectibix

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Ovarian Cancer Drug Half Way There

The single, easiest way to keep track of all the stocks that matter...Your own personalized stock watchlist!It's a 100% FREE Motley Fool service... The biotech giant announced today that its cancer drug trebananib combined with chemotherapy paclitaxel ... [Published Motley Fool - Jun 13 2013]

Entities: Amgen Inc, Ovarian Cancer, paclitaxel, Patient, progression-free survival

First reported Jun 12 2013 - Updated Jun 13 2013 - 1 reports

Cytokinetics Inc

Amgen's big Asian push triggers $75M heart drug pact for Japan

Amgen's ($AMGN) new Asia strategy is paying off for one of its development partners. Shares of Cytokinetics ($CYTK) surged 18% this morning after Amgen agreed to hand over $25 million in cash and up to $50 million in royalties in exchange for the Japanese ... [Published FierceBiotech - Jun 12 2013]

Entities: Cytokinetics Inc, Amgen Inc, Drugs, Japan

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Goldman Sachs Group Inc

Amgen's Management Presents at 2013 Goldman Sachs Healthcare Conference (Transcript)

Amgen Inc. (AMGN) 2013 Goldman Sachs Healthcare Conference June 11, 2013 2:20 PM ETTerrence Flynn - Goldman Sachs & Co. Thanks for joining us everyone. I'm Terrence Flynn, one of the biotech analysts here at Goldman Sachs. We are very pleased to welcome ... [Published Seeking Alpha - Jun 12 2013]

Entities: XGEVA, Goldman Sachs Group Inc, Enbrel, Amgen Inc, Healthcare Conference

First reported May 30 2013 - Updated May 30 2013 - 2 reports

Enbrel

Amgen's Management Presents at 2013 Deutsche Bank dbAccess Health Care Conference (Transcript)

Amgen Inc. (AMGN)2013 Deutsche Bank dbAccess Health Care ConferenceMay 30, 2013 9:20 am ET Arvind Sood - Vice President, Investor Relations Robyn Karnauskas - Deutsche Bank Research Robyn Karnauskas - Deutsche Bank Research Good morning everyone. My name ... [Published Yahoo! Finance - May 30 2013]

Entities: Enbrel, epoetin alfa, Omontys, Deutsche Bank AG, HUMIRA

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Amgen announces encouraging results from metastatic colorectal cancer analyses

Amgen Inc., a biotechnology company, has announced results from three analyses of Vectibix in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer, or mCRC. These analyses include ... [Published Individual.com - May 30 2013]

Entities: Vectibix, FOLFOX, Amgen Inc, Metastatic Colorectal Cancer

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Astellas Pharma Inc

Amgen Creates Japanese Joint Venture

Amgen Inc. on Wednesday said that it plans to expand its presence in the Japanese market through a joint venture with Tokyo's Astellas Pharma Inc., which itself has a strong presence in the Los Angeles area.The Thousand Oaks biotech giant recently signed ... [Published Los Angeles Business Journal - May 30 2013]

Entities: Amgen Inc, Astellas Pharma Inc, Joint Venture, Agensys Inc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Amgen Inc

US drugmaker forms China joint venture

The world's largest independent biotechnology firm headquartered in Thousand Oaks of southern California is tapping the market in China.As the latest move, Amgen Inc plans to form a joint venture with Chinese pharmaceutical firm Zhejiang Beta Pharma Co ... [Published CHINAdaily - May 20 2013]

Entities: Amgen Inc, China, Joint Venture

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Amgen's Phase III colorectal cancer trial meets primary endpoint

Amgen Inc., a biotechnology company, has announced that the Phase III head-to-head ASPECCT trial evaluating Vectibix versus Erbitux as a single agent for the treatment of chemorefractory metastatic colorectal cancer, or mCRC, in patients with wild-type ... [Published Individual.com - May 20 2013]

Entities: Vectibix, Erbitux, primary endpoint, Phase III, Colorectal Cancer

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Amgen, Zhejiang Beta partner to commercialize Vectibix in China

Amgen and Zhejiang Beta Pharma have signed an agreement to form a joint venture (JV) to commercialize Amgen's Vectibix (panitumumab) in the Chinese market. ... [Published PBR - News - May 14 2013]

Entities: Vectibix, Amgen Inc, China

First reported May 10 2013 - Updated May 11 2013 - 1 reports

Deals of the Week: With Option Deal, Forest Keeps An Eye On The Prize-Winner

It’s an optimistic time for pharma dealmakers, with the Dow and the Nasdaq Biotechnology Index climbing, buyers sitting on big piles of cash, and the IPO window as wide-open as it’s been in years. But for smaller companies that have long lamented that ... [Published The IN VIVO Blog - May 10 2013]

Entities: Astellas Pharma Inc, Shire plc, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd

First reported Feb 20 2013 - Updated Feb 20 2013 - 1 reports

VECTIBIX (Panitumumab) Solution [Amgen Inc]

Updated Date: Feb 19, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 20 2013]

Entities: Vectibix, Amgen Inc

First reported Jan 29 2013 - Updated Jan 29 2013 - 1 reports

Takeda presents data from post-marketing survey of Vectibix to treat olorectal cancer at ASCO GI 2013 symposium

Takeda Pharmaceutical Company Limited (Takeda) has presented the data from post-marketing survey of Vectibix for the treatment of colorectal cancer at the American Society of Clinical Oncology, 2013 Gastrointestinal Cancers Symposium (ASCO GI 2013) in ... [Published PharmaBiz - Jan 29 2013]

Entities: Vectibix, Takeda Pharmaceutical Co Ltd, gastrointestinal, Colorectal Cancer, Cancer

Quotes

"An early imbalance of deaths favoring the control arm was observed"

Ovarian Cancer Drug Half Way There [Published Motley Fool - Jun 13 2013]

...program for omecamtiv mecarbil and on Amgen's recent commitment to expand its business activities in Japan," said Robert Blum, Cytokinetics CEO. "We look forward to the integration of Japan into our collaboration's global development plan for this promising drug candidate."

Amgen's big Asian push triggers $75M heart drug pact for Japan [Published FierceBiotech - Jun 12 2013]

"We are enthusiastic in terms of doing a few more," he tells FierceBiotech. "There's a general perception that the low-hanging fruit in terms of target selection on ADCs has been used up." That's left Big Pharma looking for new ideas, giving CytomX an opening it can capitalize on...

Pfizer turns to upstart CytomX for $635M deal on armed antibody tech [Published FierceBiotech - Jun 06 2013]

Dr. Bernard Nordlinger, CHU Ambroise Pare AP-HP, Boulogne-Billancourt and Coordinator of this study, says "The objective of this trial is to determine a new standard of care for these patients." The randomized phase 2 EORTC trial will investigate if treatment with perioperative modified FOLFOX6 plus either bevacizumab or panitumumab improves...

EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy [Published News-Medical.Net - Jun 05 2013]

More Content

sort by: Date \| Relevance
Ovarian Cancer Drug Half Way There [Published Motley Fool - Jun 13 2013]
Amgen's big Asian push triggers $75M heart drug... [Published FierceBiotech - Jun 12 2013]
Amgen's Management Presents at 2013 Goldman Sac... [Published Yahoo! Finance - Jun 12 2013]
Amgen's Management Presents at 2013 Goldman Sac... [Published Seeking Alpha - Jun 12 2013]
Pfizer turns to upstart CytomX for $635M deal o... [Published FierceBiotech - Jun 06 2013]
EORTC BOS 2 trial to test efficacy of adding be... [Published News-Medical.Net - Jun 05 2013]
EORTC BOS 2 trial opens for patients with resec... [Published Medical Xpress - Jun 04 2013]
ASCO Highlights Put Variety in Spotlight [Published OncLive - Jun 01 2013]
Amgen's Management Presents at 2013 Deutsche Ba... [Published Yahoo! Finance - May 30 2013]
Amgen's Management Presents at 2013 Deutsche Ba... [Published Seeking Alpha - May 30 2013]
Assigning Credit and Blame to Biopharma R&D Chiefs [Published Oncology Business Review - May 30 2013]
Antibody-Drug Conjugates: Carbon-14 Labeling Re... [Published Drug Discovery and Development - May 30 2013]
Amgen announces encouraging results from metast... [Published Individual.com - May 30 2013]
Amgen Creates Japanese Joint Venture [Published Los Angeles Business Journal - May 30 2013]
Amgen-Astellas Collaborate - Analyst Blog [Published Quote.com Canada - May 29 2013]
Amgen forges ahead in Japan with Astellas joint... [Published FiercePharma - May 29 2013]
Amgen-Astellas Collaborate [Published Yahoo! Finance - May 29 2013]
EORTC BOS 2 Trial Evaluating Targeted Agents to... [Published Oncology Business Review - May 29 2013]
Amgen, Astellas Join Forces in Japan [Published Genetic Engineering News - May 29 2013]
Sights set on Asia, Amgen sets up JV developmen... [Published FierceBiotech - May 29 2013]
Amgen and Astellas forge long-term alliance [Published Pharma Times - May 29 2013]
Chinese firms see strong start in R [Published CHINAdaily - May 28 2013]
Amgen: Financial Analysis And Valuation [Published Seeking Alpha - May 24 2013]
Stocks in Focus: Ruckus Wireless Inc (NYSE:RKUS... [Published SBWire - May 21 2013]
US drugmaker forms China joint venture [Published CHINAdaily - May 20 2013]
Amgen's Phase III colorectal cancer trial meets... [Published Individual.com - May 20 2013]
New Analyses Identify Predictive Biomarkers For... [Published PR Newswire: Health - May 15 2013]
Amgen, Zhejiang Beta partner to commercialize V... [Published PBR - News - May 14 2013]
Deals of the Week: With Option Deal, Forest Kee... [Published The IN VIVO Blog - May 10 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Quest ... [Published Proactiveinvestors United Kingdom RSS feed - May 10 2013]